miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2

Jing Fu1, Xiaojie Xu2, Lei Kang3

  • 1Department of Endocrinology, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, People's Republic of China; Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, People's Republic of China.

Insights

MicroRNA-30a (miR-30a) represses Eye absent 2 (Eya2) expression in breast cancer cells. This miR-30a/Eya2 pathway impacts cell proliferation and migration, offering potential therapeutic targets.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • Eye absent (Eya) proteins regulate cell fate.
  • Eya2 is implicated in various cancers, but its regulation by microRNAs is unknown.

Purpose of the Study:

  • To investigate the role of microRNAs in regulating Eya2 expression.
  • To elucidate the function of the miR-30a/Eya2 axis in breast cancer.

Main Methods:

  • Investigated miR-30a binding to Eya2's 3'-untranslated region.
  • Utilized overexpression and knockdown (siRNA) of Eya2 in breast cancer cells.
  • Analyzed cell proliferation, migration, and cell cycle-related protein expression.

Main Results:

  • miR-30a directly represses Eya2 expression.
  • miR-30a inhibits breast cancer cell proliferation and migration; Eya2 overexpression rescues this effect.
  • Eya2 knockdown mimics miR-30a effects and abolishes miR-30a's regulatory ability.
  • The miR-30a/Eya2 axis modulates G1/S cell cycle progression and related proteins (cyclin A, D1, E, c-Myc).
  • miR-30a is downregulated, and Eya2 is upregulated in breast cancer patients.

Conclusions:

  • The miR-30a/Eya2 axis is crucial for breast cancer development and progression.
  • miR-30a activation or Eya2 inhibition presents a potential therapeutic strategy for breast cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K